Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 705-713, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-922131
ABSTRACT
Patients with oncogenic driver alterations of non-small cell lung cancer (NSCLC) can benefit from targeted therapy, but acquired resistance is inevitable ultimately. Epigenetic modifications, including DNA methylation, histone modifications, non-coding RNA-mediated regulate and chromatin remodeling, are important mechanisms of acquired resistance in targeted therapy of NSCLC. In recent years, studies have found that epigenetic modifications can effectively reverse drug resistance. Targeted therapy combined with epigenetic modifications may become a promising therapeutic strategy. Here, we review the progress of epigenetic mechanism in acquired resistance of targeted therapy in NSCLC, hoping to provide ideas for screening dominant population and overcoming resistance.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Carcinoma, Non-Small-Cell Lung
/
DNA Methylation
/
Epigenesis, Genetic
/
Lung Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS